Additional file 1: of A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model

Figure S1. Metabolism of 51657. Figure S2. ADR-Res cells expressing Pgp are more sensitive to 51657 than to paclitaxel. Figure S3. Normalized WT and PS19 mouse body weights over time while receiving twice-weekly dosing of vehicle or 51657 (3 mg/kg or 10 mg/kg). Figure S4. PS19 mouse organ weights were unaffected by 12 weeks of 51657 dosing. Figure S5. Quantification of NeuN-positive neurons within the CA3 region of the hippocampus of 12-month old female WT mice or vehicle- or 51657-treated female PS19 mice. Figure S6. Composite images of the three blots utilized in quantification of insoluble AcTau as shown in manuscript Fig. 5c. Figure S7. A comparison of insoluble AcTau levels in 9-month old and 12-month old female PS19 mice. Figure S8. Representative 40× images of hippocampal dentate region from brain sections of vehicle- or 51657-treated PS19 mice stained to visualize astrocytes and microglia. Table S1. Crystal data and structure refinement for CNDR-51657. Table S2. Atomic coordinates (× 104) and equivalent isotropic displacement parameters (Å2x 103) for CNDR-51657. Table S3. Bond lengths [Å] and angles [°] for CNDR-51657. Table S4. Anisotropic displacement parameters (Å2x 103) for CNDR-51657. Table S5. Hydrogen coordinates (× 104) and isotropic displacement parameters (Å2x 10 3) for CNDR-51657. (PDF 2847 kb